# Corrected and republished from: “Clinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021–2023 RSV outbreaks to investigate the immunity debt hypothesis”

## TL;DR

This paper describes a new high-throughput test for measuring RSV immunity and finds no significant change in adult antibody levels before and after recent RSV outbreaks.

## Contribution

A CLIA/GCLP-validated high-throughput RSV neutralization assay is developed and applied to investigate the immunity debt hypothesis.

## Key findings

- The assay accurately measures RSV neutralizing titers with strong correlation to ELISA results.
- RSV PCR-positive individuals had 7.5-fold higher neutralizing titers than PCR-negative individuals.
- No significant difference in RSV neutralizing titers was found in adults before and after the 2022–2023 RSV outbreak.

## Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened interest in RSV immunologic surveillance, necessitating the development of high-throughput assays assessing anti-RSV neutralizing activity. Quantitative viral neutralization remains the best correlate of protection for RSV infection and the gold standard for RSV immunological testing. Here, we developed a high-throughput RSV strain A2 focus-reduction neutralization test validated to CLIA/GCLP standards using both clinical specimens and commercially available reference sera. The assay is highly accurate, generating reference serum neutralizing titers within twofold of established assays, with an analytical measurement range between 8 and 1,798 international units (IU) per mL. Neutralizing activity measured by the assay strongly correlated with antibody titer determined via indirect ELISA (ρ = 1.0, P = 0.0014). Individuals recently having tested RT-qPCR positive for RSV had a 7.5-fold higher geometric mean neutralizing titer relative to RSV PCR negatives (P < 0.0001). The validated assay was then used to investigate the immunity debt hypothesis for resurgent RSV outbreaks in the 2022–2023 season, using adult clinical remnant sera sent for HSV-1/2 antibody testing. There was no difference in geometric mean anti-RSV neutralizing titers between sera sampled before and after the 2022–2023 RSV outbreak (P = 0.68). These data are consistent with limited changes in RSV neutralizing antibody levels in adults across the 2022–2023 RSV outbreak.

Population surveillance studies of serum neutralizing activity against RSV are crucial for evaluating RSV vaccine efficacy and vulnerabilities to new strains. Here, we designed and validated a high-throughput assay for assessing anti-RSV neutralizing activity, standardized its measurements for comparison with other methodologies, and demonstrated its applicability to real-world samples. Our assay is precise, linear, and yields measurements consistent with other standardized assays, offering a methodology useful for large-scale studies of RSV immunity. We also find no significant difference in neutralizing titers among adults between taken before and after large RSV outbreaks associated with the latter stages of the COVID-19 public health emergency, underlining the need for a greater understanding of the dynamics of serological responses to RSV infection.